Health Condition 1: B078- Other viral warts
Conditions
Interventions
Intervention1: Vitamin D: Intralesional Vitamin D 2 weekly upto 4 doses and follow up until 10th week from 1st visit.
Control Intervention1: MMR VACCINE: Intralesional MMR Vaccine 2 weekly upto 4 dose
Sponsors
MAMC
Eligibility
Inclusion criteria
Inclusion criteria: 1. Sex/Age: - Either sex from 18 â?? 60 years of age 2. Patients diagnosed with multiple plane warts ( >2) based on clinical examination.
Exclusion criteria
Exclusion criteria: 1. Patients under any systemic or topical treatment of warts for the last four weeks 2. Patients with a past history of an allergic response to vaccine or drug 3. Patients with current acute febrile illness or any bacterial infection 4. Immunosuppressed patients (HIV/Immunodeficiency syndrome/Immunosuppressants agents/etc.) 5. Pregnant or lactating women 6. Patients having past history of asthma, allergic skin disorders or convulsions 7. Patient refusal for consent 8. Treating physicianâ??s decision to give other treatment modality 9. Atypical, subclinical or dysplastic types of warts
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate: Complete disappearance of disease/lesion before or after completing the course of treatment.Timepoint: four doses of two weekly injections. Final outcome to be seen 4 weeks after last dose. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Partial response to both the drugs will be assessed by decrease in size & total number using Visual Analog Scale. 2. Frequency of Adverse Drug Reaction to both the drugs by using Naranjo ScaleTimepoint: 2 weekly dosage for 3 times followed by follow up after 1 month of last dose | — |
Countries
India
Contacts
Public ContactDr Sandeep Sharma
MAMC Agroha Hisar
Outcome results
None listed